Patents by Inventor William D. Huse
William D. Huse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8338107Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.Type: GrantFiled: November 16, 2006Date of Patent: December 25, 2012Assignees: Scripps Research Institute, Medical Research Institute, Catalyst Assets LLCInventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
-
Publication number: 20120135006Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: October 24, 2011Publication date: May 31, 2012Applicant: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 8153133Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: GrantFiled: February 17, 2010Date of Patent: April 10, 2012Assignee: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20120070447Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: October 18, 2010Publication date: March 22, 2012Applicant: MEDIMMUNE, LLCInventors: JAMES F. YOUNG, SCOTT KOENIG, LESLIE S. JOHNSON, WILLIAM D. HUSE, JEFFREY D. WATKINS, HERREN WU
-
Patent number: 7858359Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.Type: GrantFiled: November 9, 2006Date of Patent: December 28, 2010Assignees: Stratagene, Medical Research CouncilInventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
-
Patent number: 7847082Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: June 1, 2009Date of Patent: December 7, 2010Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20100303726Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: ApplicationFiled: June 10, 2010Publication date: December 2, 2010Applicant: CELLMATRIXInventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Publication number: 20100266614Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: May 11, 2010Publication date: October 21, 2010Applicant: MedImmune, LLCInventors: James F. YOUNG, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20100239574Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: February 17, 2010Publication date: September 23, 2010Applicants: MEDIMMUNE, LLC, APPLIED MOLECULAR EVOLUTION, INC.Inventors: JAMES F. YOUNG, LESLIE S. JOHNSON, WILLIAM D. HUSE, HERREN WU, JEFFRY D. WATKINS
-
Patent number: 7763248Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: May 8, 2008Date of Patent: July 27, 2010Assignee: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7763247Abstract: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: February 15, 2008Date of Patent: July 27, 2010Assignee: Cell Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7740851Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M?1, and even 1011 M?1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: GrantFiled: September 8, 2003Date of Patent: June 22, 2010Assignee: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 7700735Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: GrantFiled: March 1, 2001Date of Patent: April 20, 2010Assignee: MedImmune, LLCInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herron Wu, Jeffrey D. Watkins
-
Patent number: 7667007Abstract: The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to ?v?3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of ?v?3 by contacting ?v?3 with an enhanced LM609 grafted antibody.Type: GrantFiled: April 14, 2008Date of Patent: February 23, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: William D. Huse, Herren Wu
-
Publication number: 20100028948Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: June 1, 2009Publication date: February 4, 2010Applicant: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7635568Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: July 26, 2004Date of Patent: December 22, 2009Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20090202986Abstract: The present invention provides optimized heteromeric variable region binding fragments and antibodies comprising optimized heteromeric variable region binding fragments. Preferably, the optimized heteromeric variable region binding fragments exhibit optimized activity compared to donor heteromeric variable regions and have unvaried human frameworks. The present invention also provides methods of making the optimized heteromeric variable region binding fragments.Type: ApplicationFiled: October 28, 2004Publication date: August 13, 2009Inventors: William D. Huse, Jeffry Dean Watkins, Alain Philippe Vasserot, David Matthew Marquis, Eric Michael Smith
-
Patent number: 7566770Abstract: The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.Type: GrantFiled: July 14, 2006Date of Patent: July 28, 2009Assignee: Cell-Matrix, Inc.Inventors: Jeffry D. Watkins, William D. Huse, Ying Tang, Daniel Broek, Peter Brooks
-
Patent number: 7553489Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: December 20, 2006Date of Patent: June 30, 2009Assignee: MedImmune, LLCInventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20090023900Abstract: The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to ?v?3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of ?v?3 by contacting ?v?3 with an enhanced LM609 grafted antibody.Type: ApplicationFiled: April 14, 2008Publication date: January 22, 2009Applicant: APPLIED MOLECULAR EVOLUTION, INC.Inventors: William D. Huse, Herren Wu